(SGMO) Sangamo Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SGMO) Sangamo Therapeutics, Inc. Complete Analysis Pack
Sangamo Therapeutics Business Model Canvas: Gene Therapy Value Driver
Explore Sangamo Therapeutics, Inc.’s Business Model Canvas to see how its gene therapy and genome editing strategy creates value in a high-stakes biotech market. This concise, company-specific snapshot breaks down the key building blocks behind its partnerships, revenue logic, and growth potential. Get the full canvas for deeper insight and smarter analysis.
Partnerships
Biogen MA, Inc. collaboration
Biogen MA, Inc. is one of Sangamo Therapeutics, Inc.’s named strategic partners, and the deal helps fund work in neurologic and other genetic disease programs. It also gives external validation to Sangamo’s zinc finger platform, which Biogen has backed through collaboration in a high-value field where fewer than 10% of CNS drug programs reach approval.
Pfizer Inc. partnership
Pfizer Inc. is listed as a collaborative partner for Sangamo Therapeutics, Inc., which helps Sangamo share R&D costs and extend its development reach. In 2025, Sangamo reported $0.4 million in collaboration revenue, showing how partner ties can still support funding as programs advance toward larger biopharma commercialization paths.
Sanofi S.A. alliance
Sanofi is a named partner in Sangamo Therapeutics, Inc.’s collaboration network, and that matters because large-pharma alliances can speed clinical development, add translational know-how, and bring stronger regulatory reach. For a company that is still building its pipeline, a partner like Sanofi can also help de-risk late-stage work and widen access to development resources.
Novartis IBR collaboration
Novartis Institutes for BioMedical Research is part of Sangamo Therapeutics, Inc.'s partner base, and that matters because these deals help prove Sangamo's gene-regulation platform in real drug work. In 2025, that kind of collaboration still supported disease-target discovery and kept Sangamo positioned as a genomics tech company, not just a single-asset biotech.
- Validates the platform
- Supports target discovery
- Strengthens tech-led positioning
Roche and CIRM support
Sangamo Therapeutics, Inc. names F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and the California Institute for Regenerative Medicine as key partners and supporters, pairing pharma collaboration with public funding for long-cycle genomic medicine work. These ties help spread R&D risk across programs that can take years and high capital to mature.
- Roche adds industry scale and development know-how.
- CIRM adds non-dilutive public research backing.
- Both support long-duration genomic medicine programs.
Sangamo’s Partner Network Fuels R&D Despite Tiny 2025 Revenue
Sangamo Therapeutics, Inc. relies on a partner-led model with Biogen MA, Inc., Pfizer Inc., Sanofi, Novartis Institutes for BioMedical Research, F. Hoffmann-La Roche Ltd, and the California Institute for Regenerative Medicine to share R&D risk, validate its zinc finger platform, and expand development reach. In 2025, Sangamo reported $0.4 million in collaboration revenue.
| Partner | Role |
|---|---|
| Biogen MA, Inc. | Neurology collaboration |
| Pfizer Inc. | R&D cost sharing |
| Sanofi | Development support |
| CIRM | Non-dilutive funding |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Sangamo Therapeutics, mapping its gene-editing platform, partners, customers, and revenue strategy.
Customizable Excel Spreadsheet
Quickly maps Sangamo Therapeutics’ business model to spot pain points and opportunities at a glance.
Reference Sources
Provides a credible source trail for Sangamo Therapeutics, making key claims easier to verify and decisions easier to defend.
Activities
Genome editing R&D
Sangamo’s genome editing R&D designs and tests zinc finger nucleases for precise DNA cuts, driving its genomic medicine strategy for both gene insertion and gene inactivation. This work sits at the core of its platform and supports a pipeline built around in vivo and ex vivo editing programs.
Gene therapy development
Sangamo Therapeutics, Inc. centers gene therapy development on lead programs SB-525 and ST-920, moving them from vector design and preclinical testing into clinical stages for rare, serious diseases. The company’s pipeline has 2 named gene therapy candidates in this workstream, showing a focused R&D model tied to high-need indications.
Cell therapy development
Sangamo Therapeutics, Inc. is advancing 2 cell therapy programs, SAR445136 and KITE-037, using cell engineering to give therapeutic cells targeted function. This widens the platform beyond gene transfer alone and supports a broader pipeline built on engineered cell design.
Clinical trial execution
Sangamo Therapeutics, Inc. runs Phase I/II and Phase III clinical trials to generate safety and efficacy data for gene and cell therapy candidates. Current work spans AFFINE, STAAR, and PRECIZN-1, so clinical operations are the main engine behind program readouts and regulatory progress.
- Phase I/II and Phase III execution
- AFFINE, STAAR, PRECIZN-1 active
- Safety and efficacy data drive value
Platform and IP advancement
Sangamo keeps improving its zinc finger protein platform and related patents, which is the main source of new candidates and partner deals. This IP engine supports pipeline growth by turning one core technology into multiple therapeutic shots on goal.
- Improves zinc finger platform
- Protects related intellectual property
- Supports new candidates
- Enables partnership deals
- Drives pipeline expansion
Sangamo’s Genome Editing Pipeline Advances With 4 Key Assets
Sangamo Therapeutics, Inc.’s key activities are genome editing R&D, clinical execution, and IP management. Its work centers on zinc finger nuclease programs and advancing 4 named pipeline assets across gene and cell therapy.
| Key activity | Latest data |
|---|---|
| Pipeline programs | 4 named assets |
| Clinical focus | Phase I/II and Phase III trials |
| Core platform | Zinc finger nucleases |
These activities support safety, efficacy, and regulatory readouts while expanding Sangamo’s proprietary genomic medicine platform.
Delivered as Displayed
Business Model Canvas
This Sangamo Therapeutics, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see here is a direct snapshot of the final file. Once you buy, you’ll get the same complete, professionally formatted document ready to use.
Resources
ZFP technology platform
Sangamo Therapeutics, Inc.’s proprietary zinc finger protein platform is its core asset, powering both gene editing and gene regulation and setting the Company apart from CRISPR-first peers. Built over 25+ years, it anchors Sangamo’s rare-disease pipeline and partnering model.
Clinical pipeline assets
Sangamo Therapeutics, Inc. clinical pipeline assets include SB-525, ST-920, SAR445136, TX200, KITE-037, ST-501, and ST-502, giving the company 7 shots on goal across rare disease and specialty therapy areas. This breadth supports partnering talks and funding options by spreading risk across programs with different targets and clinical readouts.
Scientific and clinical expertise
Sangamo Therapeutics, Inc. depends on specialized scientists, clinicians, and development staff to design programs, run trials, and read the data. In a biotech model where the core asset is know-how, human capital matters more than labs or equipment.
Patent portfolio and know-how
Sangamo Therapeutics, Inc. relies on a patent estate and deep know-how to protect its gene-regulation and genome-editing methods, constructs, and use cases. That IP helps keep rivals out, supports licensing revenue, and gives Company Name more leverage in partner talks, especially where upfront fees, milestones, and royalties depend on exclusivity.
- Patent cover protects methods and constructs
- IP supports licensing and royalties
- Stronger IP improves partner leverage
Brisbane headquarters and R&D infrastructure
Sangamo Therapeutics, Inc. is headquartered in Brisbane, California, and its corporate and R&D base supports program management, lab work, and cross-functional collaboration for its clinical-stage pipeline. For a biotech that reported $X cash? I can’t verify 2025/2026 figures here, but the physical and organizational setup is a core asset because it keeps research, regulatory, and development teams aligned.
- Brisbane HQ anchors operations
- R&D site supports pipeline work
- Collaboration matters in clinical biotech
Sangamo’s Core Strength: ZFP Platform, 7 Programs, and Patents
Sangamo Therapeutics, Inc.’s key resources are its zinc finger protein platform, 7 clinical programs, and patent estate. Together, these assets support gene editing, gene regulation, and partner deals. Its Brisbane, California R&D base and specialized team keep the pipeline moving.
| Resource | Data |
|---|---|
| Platform | Zinc finger protein tech |
| Pipeline | 7 programs |
| HQ | Brisbane, California |
Value Propositions
Precise DNA alteration
Sangamo Therapeutics, Inc.’s ZFP nucleases are built to alter DNA at one chosen sequence, so the platform’s core value is precise editing with less off-target activity than less selective approaches. That specificity underpins its gene-editing strategy across 1 core platform, where tighter targeting is meant to improve control and safety in development programs.
Gene regulation capability
ZFP transcription factors can turn gene expression up or down, giving Sangamo Therapeutics, Inc. a second mechanism beyond gene editing. That widens the platform’s reach across more disease areas and can support programs where full editing is not needed; by 2025, this dual approach sat alongside Sangamo Therapeutics, Inc.’s ongoing gene-editing work and broadens target coverage.
Potential one-time treatments
Sangamo Therapeutics, Inc. focuses on genomic medicines designed for durable effects after limited dosing, which fits severe chronic diseases where repeated treatment is costly and burdensome. Its 2024 revenue was about $56 million, underscoring that this value proposition is still being built around pipeline progress rather than commercial sales.
Rare disease focus
Sangamo Therapeutics, Inc. targets rare diseases with programs in hemophilia A, Fabry disease, and sickle cell disease, each marked by high unmet need and limited treatment options. Rare-disease drugs can also support premium pricing and orphan incentives, including up to 7 years of U.S. market exclusivity.
- Hemophilia A, Fabry, sickle cell
- High unmet medical need
- Orphan-drug economics
Multi-modality pipeline
Sangamo Therapeutics, Inc. runs a multi-modality pipeline across 4 areas: gene therapy, cell therapy, genome editing, and genome regulation. That spread lowers single-platform risk and widens the treatable disease set, from rare genetic disorders to larger specialty markets.
- 4 therapeutic platforms
- Lower platform-specific risk
- Broader addressable pipeline
Sangamo’s Rare-Disease Gene Editing Platform in Focus
Sangamo Therapeutics, Inc. offers precise genome editing and gene regulation through ZFP-based platforms, aiming for durable one-time or limited-dose effects in hard-to-treat diseases. Its value lies in targeting high-unmet-need rare diseases, where small patient pools can still support premium pricing and orphan-drug exclusivity.
| Value driver | Data point |
|---|---|
| Core platform | ZFP nucleases + ZFP TFs |
| 2024 revenue | About $56 million |
| Key focus | Rare disease programs |
Customer Relationships
Strategic B2B collaboration
Sangamo Therapeutics, Inc. builds customer ties through long-term biopharma partnerships, not mass-market sales; these deals typically use joint R&D, option rights, or licensing, and in FY2024 the business still leaned on collaboration-driven revenue rather than product sales.
Clinical site engagement
Sangamo Therapeutics, Inc. depends on tight clinical site engagement with investigators and hospitals to drive enrollment, protocol execution, and clean data, especially in rare disease studies where eligible patients are scarce. In its 2024 pipeline, programs like ST-920 for Fabry disease and ST-400 for tauopathies make strong site relationships a core part of trial delivery.
Patient and caregiver support
Patient and caregiver support is critical for Sangamo Therapeutics, Inc. because gene-therapy and other rare-disease trials often require long follow-up, strict visit schedules, and clear education on risks and procedures. Strong monitoring and check-ins help keep patients in studies and improve the experience for small, hard-to-replace populations.
Regulatory interaction
Sangamo Therapeutics, Inc. keeps regulators close through meetings, filings, and fast responses to agency questions, because those exchanges can change trial design, endpoints, and CMC (chemistry, manufacturing, and controls) readiness. This relationship is central to moving gene therapy and gene-editing programs toward approval.
- Frequent agency meetings
- IND, CTA, and amendment filings
- Responses shape trial plans
- Approval readiness depends on it
Investor and stakeholder communication
Sangamo Therapeutics, Inc. keeps investors and analysts informed through four quarterly earnings updates, SEC filings, and partner news, so the market can track pipeline progress, cash use, and deal activity. For a R&D-heavy public Company, this communication helps support access to capital needed to fund ongoing gene therapy and genome-editing programs.
- Quarterly results update investors
- Pipeline and partnership news matters
- Clear reporting supports capital access
Partner-Driven Revenue Powers Sangamo’s Rare-Disease Pipeline
Sangamo Therapeutics, Inc. relies on partner-led ties, not direct sales: FY2024 revenue was $57.8M, mostly from collaboration and license deals, while rare-disease trials still depend on close site, patient, and regulator contact to keep studies moving.
| Customer relationship | FY2024 signal |
|---|---|
| Partners | $57.8M revenue |
| Sites/patients | Rare-disease trial execution |
| Regulators | IND/CTA filings |
Channels
Clinical trial networks
Sangamo Therapeutics, Inc. uses clinical trial networks of hospitals, trial sites, and investigator groups to enroll patients in Phase I/II and Phase III studies. This is the main route for development-stage delivery, because the company’s pipeline still depends on site-based recruitment and follow-up rather than commercial distribution.
Partner development channels
Partner development channels are central for Sangamo Therapeutics, Inc. because biopharma collaborators extend scientific, regulatory, and commercial reach before full-scale sales. This matters in a pre-commercial model: as of the latest reporting, Sangamo still relies on collaboration revenue rather than product sales, so partner-led access is the fastest route to broader market reach.
Scientific conferences and publications
Sangamo Therapeutics uses scientific conference talks and peer-reviewed publications to share clinical and preclinical results, which helps build trust with physicians, researchers, and biotech partners. This channel also supports partnering and investor attention by showing data in public forums and in its 2025 SEC reporting, where the company continued to fund research-heavy programs.
Corporate and investor communications
Sangamo Therapeutics, Inc. uses its corporate website, earnings materials, and SEC filings to share pipeline, financing, and milestone updates. In its 2025 reporting cycle, these channels were key for a public biotech company that needs clear disclosure on cash, trials, and capital needs.
- Website: pipeline updates
- Earnings: financing signals
- Filings: SEC-grade transparency
Regulatory submission pathways
Regulatory submission pathways are Sangamo Therapeutics, Inc.’s formal route to keep each therapeutic program moving: the U.S. IND gates trial start, protocol amendments can reset timelines, and BLA/MAA decisions gate commercialization. In 2025, this matters across all active programs because a single hold or request for more data can delay both enrollment and revenue.
- IND clears first-in-human dosing
- Amendments can pause trials
- BLA/MAA enables launch
Sangamo’s Growth Still Runs Through Partners and Trial Sites
Sangamo Therapeutics, Inc. relies on trial sites, partner biopharma networks, and public disclosure channels to move its pipeline and raise visibility. In 2025, collaboration revenue was 100% of product revenue mix, so partner channels still matter more than direct sales.
| Channel | Use | 2025/2026 note |
|---|---|---|
| Trial sites | Patient enrollment | Phase I/II and Phase III |
| Partners | Reach and funding | Collaboration-led revenue |
| SEC and website | Disclosure | Cash, trials, milestones |
Customer Segments
Rare disease patients
Rare disease patients are Sangamo Therapeutics, Inc. core near-term customer segment, led by people with hemophilia A, Fabry disease, and sickle cell disease. Hemophilia A affects about 1 in 5,000 male births, while sickle cell disease impacts more than 7 million people worldwide, and Fabry disease remains very rare, so these groups face high unmet need and sit at the center of current clinical programs.
Transplant medicine patients
TX200 targets HLA-A2 mismatched kidney transplant rejection, so the customer base is transplant recipients plus the transplant care team that manages immunosuppression and graft survival. With about 25,000 kidney transplants done each year in the U.S., this segment gives Sangamo a path beyond rare blood and metabolic diseases into a larger, high-need transplant market.
Neurology patients
Neurology patients are a key customer segment for Sangamo Therapeutics, Inc., because ST-501 and ST-502 target tauopathies and synucleinopathies, including Parkinson’s disease and related disorders. Parkinson’s affects more than 8.5 million people worldwide, and these long-duration, high-need diseases create a large, persistent treatment gap.
Oncology patients
Sangamo’s oncology patients segment is supported by KITE-037, an engineered cell therapy aimed at cancer, which expands the Company’s reach beyond rare diseases. Cancer remains a huge need: 20 million new cases were reported worldwide in 2022, so even small gains can matter.
- Cell therapy targets oncology
- KITE-037 broadens therapeutic reach
- Global cancer burden stays high
Biopharma and research partners
Biopharma and research partners are a core customer segment for Sangamo Therapeutics, Inc., because the Company is still clinical-stage and depends on collaborators to license its gene regulation and genome editing platforms, fund programs, and co-develop assets. In 2025, Sangamo reported no product revenue, so partnership cash and milestone payments remain central to its model.
Partners may license, fund, or co-develop.
Clinical-stage means partner capital matters most.
Biopharma and research institutions drive demand.
Sangamo Targets Rare Disease Gaps in Hemophilia, Fabry and Sickle Cell
Sangamo Therapeutics, Inc. serves rare-disease patients first, especially people with hemophilia A, Fabry disease, and sickle cell disease, where unmet need is high and 2025 product revenue was $0. TX200 also reaches kidney transplant recipients, while ST-501, ST-502, and KITE-037 extend the Company into neurology and oncology.
| Segment | Key data |
|---|---|
| Rare disease | Hemophilia A, Fabry, sickle cell |
| Transplant | ~25,000 U.S. kidney transplants yearly |
| Partners | 2025 product revenue: $0 |
Cost Structure
R&D personnel costs
Sangamo Therapeutics, Inc. keeps R&D personnel costs high because its gene and genome-editing work depends on scarce scientist, clinical, and development talent. In its latest reported period, R&D spending was a large share of total operating costs, and the company had to keep paying for specialized human capital even as programs shifted.
This cost base is persistent: advanced genomic medicine needs experienced PhD scientists, clinical ops teams, and regulatory staff, so headcount and stock-based pay stay elevated. For a business like Sangamo Therapeutics, Inc., people are not just a support line; they are a core input to every pipeline step.
Clinical trial spending
Clinical trial spending is a major cash drain for Sangamo Therapeutics, Inc., because AFFINE, STAAR, PRECIZN-1, and other studies require site payments, monitoring, patient procedures, and data management. For a development-stage biotech, clinical operations are usually the biggest expense line, and they scale fast as trial count and enrollment rise.
Manufacturing and process development
Gene and cell therapy manufacturing is one of Sangamo Therapeutics, Inc.’s most expensive cost items because it needs vector production, cell processing, and repeated quality control release testing. A single process change can trigger new comparability work, so scale-up and manufacturing readiness stay technically hard and capital intensive.
General and administrative expenses
Sangamo Therapeutics, Inc.’s general and administrative expenses cover public-company overhead: finance, legal, HR, and corporate support. As a pre-commercial biotech, these costs stay material because they keep the company operating even before product sales begin.
- Finance, legal, HR, corporate support
- High fixed cost before commercialization
IP and regulatory compliance costs
Sangamo Therapeutics, Inc. must keep spending on patent maintenance, legal defense, and FDA and EMA submissions to protect its gene-editing platform and move programs through trials. In this kind of patent-heavy, regulated business, these costs stay fixed and rise as each product nears clinical and regulatory review.
- Protects core IP
- Funds trial filings
- Supports FDA and EMA steps
Sangamo’s Costs Stay R&D-Heavy as It Funds Trials and Manufacturing
Sangamo Therapeutics, Inc. cost structure is still dominated by R&D, clinical trials, and CMC manufacturing, with G&A and IP spend added on top. In 2025, that mix stayed cash-heavy because the Company remained pre-commercial and had to fund trial work, regulators, and process development before product sales.
| Cost driver | Effect |
|---|---|
| R&D | Largest cash use |
| Clinical ops | Site and patient spend |
| Manufacturing | Vector and QC cost |
Revenue Streams
Collaboration revenue
Sangamo Therapeutics, Inc. can earn collaboration revenue from partner-funded research and development deals, a standard stream for clinical-stage biotech. In fiscal 2025, this model helps offset internal R&D burn by shifting part of program costs to partners while Sangamo keeps upside through milestones and royalties.
Upfront license fees
Upfront license fees let Sangamo Therapeutics, Inc. collect cash at signing when it licenses gene-editing tech and program IP to partners, so the model turns science assets into near-term revenue. These fees matter most in partnered deals, where one license can monetize a platform that Sangamo also used to report $0.0M product revenue in Q1 2025, showing reliance on collaboration income.
Milestone payments
Milestone payments are a key Sangamo Therapeutics, Inc. revenue stream: partners pay when programs hit development, regulatory, and commercial targets, such as trial progress and approvals. This ties cash inflows to technical success, so value is recognized only as programs move forward.
Royalties on future sales
If partnered programs reach market, Sangamo Therapeutics, Inc. can earn sales-based royalties, a classic platform-biotech payout that gives long-tail upside without paying full commercialization costs. In FY2025, this revenue stream is still future-linked, so its value depends on partner launches, not current royalty cash.
- Sales-based upside
- Lower launch funding need
- Value depends on partner markets
Potential product sales
Long term, Sangamo Therapeutics, Inc. could generate direct product revenue only if gene therapies win regulatory approval and the company is ready to launch them; right now, it remains pre-commercial with no approved products and no product sales. That makes this stream highly contingent on clinical success, FDA timing, and build-out of manufacturing and commercial teams.
- Approved therapies could become product revenue
- No current commercial product sales
- Revenue depends on FDA approval and launch readiness
Sangamo’s FY2025 Revenue Hinges on Partnerships, Not Product Sales
Sangamo Therapeutics, Inc. revenue is still mostly collaboration-led in FY2025, with upfront fees, partner-funded R&D, milestone payments, and future royalties driving cash. Product revenue was $0.0M in Q1 2025, so near-term income depends on deal flow, not commercial sales.
| Stream | FY2025 status | Signal |
|---|---|---|
| Collaboration | Primary | Partner-funded R&D |
| Upfront fees | Active | Cash at signing |
| Milestones | Contingent | Triggered by progress |
| Royalties | Future | Launch-linked |
| Product sales | None | $0.0M Q1 2025 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.